NCT06595563 2026-02-19
ZEPHIR-02
Jules Bordet Institute
Phase 2 Recruiting
Clinical Trials
3 trialsNCT06551116 2025-09-05
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine
Recruiting
NCT06278870 2024-02-26
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Recruiting